NLS Pharmaceutics AG (NLSP)
Company Info
Highlights
$10.46M
-$2.93
-$5.70K
-$1.94M
$1.30 - $16.00
$6.00
2.51%
0.95
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
NLS Pharmaceutics AG (NLSP) returned 10.90% year-to-date (YTD) and -66.29% over the past 12 months.
NLSP
10.90%
53.44%
-28.44%
-66.29%
-55.19%
N/A
N/A
^GSPC (Benchmark)
0.52%
6.32%
-1.44%
12.25%
12.45%
14.20%
10.84%
Monthly Returns
The table below presents the monthly returns of NLSP, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 18.01% | -26.10% | -16.30% | -4.42% | 58.97% | 10.90% | |||||||
| 2024 | -22.02% | -15.91% | -53.46% | -22.39% | 0.93% | 53.83% | 1.15% | -32.04% | -14.99% | -28.40% | -6.89% | -37.57% | -91.06% |
| 2023 | 0.78% | 10.00% | 6.29% | -12.50% | -20.30% | 3.77% | -15.65% | 9.94% | -31.37% | -5.71% | -36.38% | 40.49% | -54.27% |
| 2022 | -18.92% | 32.22% | 18.49% | -39.21% | -20.66% | -13.65% | -37.02% | 33.83% | 25.28% | -15.73% | 58.85% | 55.42% | 16.22% |
| 2021 | -1.04% | 41.26% | -9.41% | -5.74% | -8.99% | -17.20% | -5.00% | 1.21% | -13.60% | -6.02% | -45.32% | -61.59% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of NLSP is 25, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for NLS Pharmaceutics AG (NLSP) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the NLS Pharmaceutics AG. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NLS Pharmaceutics AG was 99.44%, occurring on Mar 28, 2025. The portfolio has not yet recovered.
The current NLS Pharmaceutics AG drawdown is 99.00%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.44% | Mar 15, 2021 | 1016 | Mar 28, 2025 | — | — | — |
| -35.41% | Feb 12, 2021 | 15 | Mar 5, 2021 | 5 | Mar 12, 2021 | 20 |
| -9.34% | Feb 1, 2021 | 1 | Feb 1, 2021 | 2 | Feb 3, 2021 | 3 |
| -7.69% | Feb 5, 2021 | 2 | Feb 8, 2021 | 3 | Feb 11, 2021 | 5 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NLS Pharmaceutics AG over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of NLS Pharmaceutics AG, comparing actual results with analytics estimates.
Valuation
The Valuation section provides an overview of how NLS Pharmaceutics AG is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NLSP relative to other companies in the Biotechnology industry. Currently, NLSP has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NLSP in comparison with other companies in the Biotechnology industry. Currently, NLSP has a P/B value of 4.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |